Sensei Biotherapeutics, Inc. (SNSE)
NASDAQ: SNSE · Real-Time Price · USD
0.450
+0.020 (4.63%)
At close: Dec 20, 2024, 4:00 PM
0.468
+0.018 (4.11%)
After-hours: Dec 20, 2024, 6:08 PM EST
Sensei Biotherapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Selling, General & Admin | 13.85 | 18.67 | 19.81 | 15.82 | 7.53 | 4.09 | |
| Research & Development | 18.73 | 18.3 | 30.38 | 21.66 | 11.19 | 8.35 | |
| Operating Expenses | 32.58 | 36.96 | 50.19 | 37.48 | 18.71 | 12.44 | |
| Operating Income | -32.58 | -36.96 | -50.19 | -37.48 | -18.71 | -12.44 | |
| Interest Expense | -0.1 | -0.14 | -0.22 | -0.67 | -1.69 | -2.26 | |
| Interest & Investment Income | 2.85 | 3.62 | 1.78 | 0.8 | - | - | |
| Other Non Operating Income (Expenses) | -0.85 | -1.27 | 0.25 | 0.61 | 1 | -1.97 | |
| EBT Excluding Unusual Items | -30.69 | -34.76 | -48.37 | -36.75 | -19.41 | -16.67 | |
| Merger & Restructuring Charges | 0.1 | -0.1 | - | - | - | - | |
| Gain (Loss) on Sale of Investments | 0.78 | 1.06 | -0.22 | -0.62 | - | - | |
| Gain (Loss) on Sale of Assets | - | -0.3 | - | - | - | - | |
| Other Unusual Items | - | - | - | 0.57 | 0.05 | -0.08 | |
| Pretax Income | -29.8 | -34.1 | -48.59 | -36.79 | -20.1 | -16.74 | |
| Earnings From Continuing Operations | - | -34.1 | -48.59 | -36.79 | -20.1 | -16.74 | |
| Net Income | -29.8 | -34.1 | -48.59 | -36.79 | -20.1 | -16.74 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | 0.1 | 3.8 | |
| Net Income to Common | -29.8 | -34.1 | -48.59 | -36.79 | -20.2 | -20.54 | |
| Shares Outstanding (Basic) | 25 | 28 | 31 | 28 | 2 | 0 | |
| Shares Outstanding (Diluted) | 25 | 28 | 31 | 28 | 2 | 0 | |
| Shares Change (YoY) | -14.70% | -8.96% | 10.80% | 1618.88% | 338.85% | 0.02% | |
| EPS (Basic) | -1.19 | -1.22 | -1.58 | -1.33 | -12.53 | -55.92 | |
| EPS (Diluted) | -1.19 | -1.22 | -1.58 | -1.33 | -12.53 | -55.92 | |
| Free Cash Flow | -25.19 | -32.2 | -39.35 | -32.29 | -18.91 | -8.62 | |
| Free Cash Flow Per Share | -1.00 | -1.15 | -1.28 | -1.17 | -11.73 | -23.48 | |
| EBITDA | -31.26 | -35.61 | -48.84 | -36.8 | -18.5 | -12.36 | |
| D&A For EBITDA | 1.32 | 1.35 | 1.35 | 0.69 | 0.21 | 0.07 | |
| EBIT | -32.58 | -36.96 | -50.19 | -37.48 | -18.71 | -12.44 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.